ApoB

Dr. Andrew Huberman Highlights ApoB as Key Risk Factor

Huberman's channel surfaces ApoB primarily through long-form conversations with Peter Attia, where ApoB is repeatedly named as one of the key, trackable risk factors for atherosclerosis. In one episode the discussion of the major causes of death starts with atherosclerosis as the leading killer globally and highlights apolipoprotein B (apoB) alongside blood pressure and smoking as key risk factors to manage. In another, ApoB is described as the primary causative agent of atherosclerosis, with blood work to track ApoB framed as something to do early in life. Huberman's coverage is endorsing the importance of measuring and managing ApoB rather than offering an independent, native deep dive.

3 more clips

• 10:01 · Improve Vitality, Emotional & Physical Health & Lifespan | Dr. Peter Attia (Guest: Peter Attia)
• 04:49 · Exercise, Nutrition, Hormones for Vitality & Longevity | Dr. Peter Attia (Guest: Peter Attia)
• 54:30 · Exercise, Nutrition, Hormones for Vitality & Longevity | Dr. Peter Attia (Guest: Peter Attia)

Dr. Peter Attia Champions ApoB as the Superior Marker

Attia is the definitive ApoB voice in this dataset, with multiple dedicated episodes. His core thesis: ApoB concentration is the most accurate biomarker for cardiovascular risk because it counts all atherogenic particles (LDL, VLDL, Lp(a)), making it superior to LDL-C; standard 10-year risk algorithms fail because they lean on age and sex while ignoring the underlying atherosclerosis; and Mendelian randomization provides strong evidence that ApoB is causal, not just correlated. On management, he argues for early and aggressive reduction — targeting the low ApoB levels seen in children (he cites roughly 20-40 mg/dL) and a ceiling around 60 mg/dL for people in their late 30s/early 40s. He notes diet (less saturated fat and carbohydrate, lower triglycerides, upregulated LDL receptors) helps but is often insufficient to reach optimal targets, so he uses pharmacology — a PCSK9 inhibitor, bempedoic acid, ezetimibe, and statins — to close the gap. This is an explicitly clinical position.

…been estimated and let's bring this all back in terms of some other work you've done which is understanding the role of triglyceride in apob so let's start with the basic you go to the doctor you get a set of labs done and the LDL number comes back at 140 milligrams per deciliter is that actually what it is or is that an estimation that's an estimation it's almost always a calculation and there are at least eight different methods to calculate LDL cholesterol so if there are eight different methods they don't all give the same answer or you wouldn't have eight different methods LDL cholesterol can also be measured directly that assay…

▶ 36:38 · 229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB

3 more clips

• 06:23 · Cardiovascular disease & why we should change the way we assess risk | The Peter Attia Drive Podcast (Guest: Alan Sniderman)
• 00:33 · How early and aggressive lowering of apoB could change the course of ASCVD | The Peter Attia Drive
• 00:35 · How to lower your apoB

Dr. Rhonda Patrick Treats ApoB as the Better Metric

Rhonda Patrick's channel treats ApoB as the better metric on two fronts. In her interview with Peter Attia, she platforms the framing that, while total cholesterol was once the focus, ApoB is a superior predictor of risk because it represents the total burden of atherogenic particles, and that ApoB's concentration is the critical marker for cardiovascular risk. Separately, in her own CHORIBar segment, she discusses ApoB-containing lipoproteins (like LDL) as the particles that deliver lipids and drive atherosclerosis when deposition outpaces removal — consistent with treating ApoB particle burden, not just cholesterol level, as what matters. She does not lay out a numeric ApoB target of her own in the analyzed videos.

So there so there's two basic types of lipoprotein particles. There's those that contain this thing called apo B that's on uh LDL V bl and kyomicrons and the function of that type of uh B containing apol lipoprotein is to deliver uh lipids to sites that need it whether it's for uh growth or whether it's for repair and when the vascu is being uh I guess affected by chronic injury due to either high blood pressure or chronic inflammation, it needs uh these these building materials to be delivered from the liver or from the from the circulation.

▶ 01:06 · CHORIBar in Focus: Effects on Cholesterol Profile

2 more clips

• 02:52 · Dr. Peter Attia on Mastering Longevity — Insights on Cancer Prevention, Heart Disease, and Aging (Guest: Peter Attia)
• 07:54 · Dr. Peter Attia on Mastering Longevity — Insights on Cancer Prevention, Heart Disease, and Aging (Guest: Peter Attia)

Dr. Mark Hyman Recommends Advanced Lipid Testing

Mark Hyman reaches the same destination as Attia by a metabolic-health route. He argues that traditional cholesterol tests are insufficient and that advanced lipid particle analysis — including ApoB and Lp(a) — is a better indicator of cardiovascular risk than standard LDL measurements, pointing out that many heart-attack victims have "normal" LDL. He frames high ApoB as correlating with insulin resistance and poor metabolic health, and groups it with CRP as part of a fuller risk picture. His emphasis is on getting these advanced markers tested (e.g., via comprehensive lab panels) and on addressing the underlying insulin resistance and diet that drive an unhealthy particle profile.

…consumption that was causing heart disease now this is called the diet heart hypothesis which basically focus on cholesterol as a primary culprit and because saturated fat raises LDL cholesterol it was assumed that heart disease was the result of saturated fat but now thanks to systems-based Medicine were and many more studies that have followed on from this oral oral data that we'll talk about in the 50s 60s and 70s We Now understand that this is is much more complex and there's a lot more Nuance into how our lipids managed by our environment and how our biology works and the inner uh workings of our physiology when it comes to heart…

▶ 02:34 · Hidden Sources Of Heart Attacks & How To Prevent Them | Dr. Mark Hyman

2 more clips

• 00:44 · Hidden Sources Of Heart Attacks & How To Prevent Them | Dr. Mark Hyman
• 05:28 · Longevity Toolkit: An Effective Way To Fix Metabolic Health & Stay Young | Dr. Mark Hyman

What do experts agree on about apob?

The experts who cover it agree: ApoB — the count of atherogenic particles — is a more accurate predictor of cardiovascular risk than standard LDL-C, and it's worth measuring (with a doctor) rather than relying on a basic cholesterol panel. Four of the five experts endorse this; Bryan Johnson has no direct coverage in the analyzed videos.

Where do the experts disagree on apob?

How aggressively and how early to lower ApoB is the main split: Attia advocates pushing ApoB to childhood-low levels starting young, while the other experts endorse measuring/lowering ApoB without committing to those specific aggressive targets in the analyzed videos. Diet vs. medication emphasis differs: Attia is explicit that lifestyle change alone is often insufficient to hit optimal ApoB targets and leans on pharmacology, whereas Hyman frames insulin resistance, diet, and lifestyle as the root drivers to address first. Attia engages heavily with statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors as tools to lower ApoB; the other experts in this report focus more on the measurement-and-testing argument than on a specific drug protocol.

How strong is the expert consensus on apob?

The consensus on apob scores 3.9/5 — a strong level of agreement across Huberman, Attia, Patrick, Johnson, and Hyman, based on their public videos.